September 2025 updates to the Universal Influenza Vaccine Technology Landscape include the following: 

• Collaborative funding from the UK and Canadian governments announced for the development of broadly protective influenza vaccines combining next-generation vaccine platform technologies with ConserV Bioscience’s Flu-v, consisting of peptides from conserved regions of influenza M1, M2, NP-A, and NP-B proteins.
• Optimized bioprocess parameters for chimeric HA (cHA) inactivated split vaccine production, critical to meet regulatory requirements for phase 1 clinical trials, defined in Scherm 2025
• Styles 2025 evaluated immunogenicity and efficacy in the presence of pre-existing immunity of an influenza virus chimeric HA (cH8/1 and cH5/1) vaccine prime-boost regimen in rhesus macaques using two types of mRNA platform technologies, non-replicating (mRNA-LNP) and self-amplifying (sam-MDNP).
• Duration and mechanism of heterosubtypic mucosal and systemic antibody and T cell responses induced by FluGen’s M2SR (M2-deficient single-replication influenza virus) vaccine in a murine model, described in Sarawar 2025
• New mucosal adenoviral vector vaccine (Ad-HA2) vaccine candidate, expressing a consensus HA stem sequence derived by bioinformatic analysis of all H3 strains, described in Zhang 2025
• Sangesland 2025 demonstrated that cynomolgus macaques can recapitulate human public broadly neutralizing antibody responses to the HA stem following vaccination with H1ssF, a ferritin nanoparticle displaying stabilized HA stem immunogens, adjuvanted with AF03, highlighting the value of the macaque model for translational vaccinology.

For more recent updates and additional information, see the Landscape.